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We report here the synthesis of novel 5'-linked oligodeoxynucleotides, both normal phosphodiester and phosphorothioate 
analogs, in which a covalently attached group at the Y-terminus is an anthraquinone. These compounds represent a new 
class of antisense compounds inwhich the base sequence of the oligodeoxynucleotide serves to deliver a nuclease-resistant 
reactive drug-like molecule to a cellular target nucleic acid (mRNA or DNA). 
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1. INTRODUCTION 
The prospects of antisense oligodeoxynucleo- 
tides (ODNs) has attracted a great deal of attention 
in view of the possibility of selective gene regula- 
tion, and the consequent therapeutic mplications 
[1,2]. The selection of methylphosphonate (P-
CH3) [3,4] or phosphorothioate (P-S) [5,6] modi- 
fied ODNs to provide nuclease resistance has 
greatly enhanced the possibility that such antisense 
ODNs could be used in vivo. Indeed, an antisense 
effect has been shown to occur in vitro for HIV in- 
fection in chronically infected T cells [7]. Similar 
antisense ffects have been reported with normal 
and S-ODNs in cancer ceils in which oncogenes are 
overexpressed [8,9], although complete inhibition 
of expression was not achieved. In these cases, the 
S-ODNs were not found to be toxic to the cells, 
although some of the normal ODNs were 
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somewhat toxic, presumably due to nuclease diges- 
tion to mononucleotides [7,10]. 
These results, while encouraging for the general 
strategy of using antisense ODNs as drugs, ignore 
two important factors, one of which is the high 
cost of producing such drugs, making the ap- 
proach interesting, but possibly impractical. The 
other concerns the fact that although a cell surface 
receptor protein that may be involved in ODN 
transport has recently been identified [11,12], the 
S-ODNs are very slowly transported by this 
mechanism [11,13]. Thus, for both these reasons, 
cost and cellular uptake, there is a need to increase 
the potency of the antisense compounds. 
Since ODNs appear to produce translation arrest 
by an RNase H mechanism, it may be argued that 
the destruction of the mRNA [14,15], the main 
target in the antisense oligo approach, occurs 
without he need for an attached chemical moiety. 
Nevertheless, everal types of covalently attached 
compounds have been described. Helene and co- 
workers [16,17] have used 3'-linked intercalative 
groups (mainly acridines) in order to increase the 
binding capability of a short ODN in binding to its 
complementary target sequence. They have also 
linked proflavin to a terminal thiophosphate group 
at either the 3'- or 5'-end of an octadeoxy- 
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thymidylate [18]. The proflavin was then activated 
by light irradiation. Knorre and co-workers [19,20] 
have produced a series of covalently attached 
alkylating groups that are designed to modify the 
complementary strand. These workers have also 
attached cholesteryl groups to oligos in an attempt 
to increase the rate of cellular uptake [21]. EDTA 
or other chelating agents have also been attached 
to the oligo in order to bind a metal ion and bring 
about destruction of DNA [22-25]. 
Our strategy is to attach groups onto oligos at 
the 5'-terminus using the intermediate linked 
phosphoramidite synthons in the automatic syn- 
thesizer [13,26]. This is the most efficient approach 
since the 3'-terminus is attached to the solid sup- 
port, and the entire synthesis occurs in the syn- 
thesizer. In some cases the linkage to the group is 
not stable under the conditions of acid and base 
used in the automated synthesis, and therefore a
linker attached to a phosphoramidite was used, 
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Fig.l. Structure of an anthraquinone 5' -linked to a 
phosphorothioate oligodeoxynucleotide analog via a methylene 
linker (AQ-m-S-ODN). 
followed by subsequent attachment of the group 
[26]. In the case of the 9-aminoacridine bond, 
which is susceptible to cleavage by NH4OH, 
substitution of NaOH prevents cleavage of the 
linked group [27,28]. 
We have previously attached acridines using 
these methods [13,26], and describe here the pro- 
ducts containing anthraquinones (fig.l). This 
group was chosen because it is a potential radical- 
producing moiety, that does not necessarily require 
the presence of a metal ion or optical activation, 
and can act very much like a series of well-known 
radical-producing anti-cancer drugs [29], such as 
adriamycin. Given the possibilities of chemical 
variation, including the length of the linker arm, as 
well as the ODN itself, and the attached group, this 
compound represents a novel approach to the in- 
crease in potency of the antisense method. 
2. MATERIALS AND METHODS 
2.1. Preparation of anthraquinone-piperazinyl derivative 
A mixture of 1-chloroanthraquinone (1 g) and 1-(2-hydroxy- 
ethyl)piperazine (5 g) was heated at 150°C for 30 min. After 
cooling to room temperature, water was added, and the 
material filtered. Recrystallization from chloroform gave 
1-[1-(2-hydroxyethyl)piperazinyl]anthraquinone (f g.2) in a 
yield of 79070 (1.1 g); m.p. 168°C; tH NMR spectrum (CDC13): 
8.28 (1H, doublet, C8), 8.24 (IH, doublet, C5), 7.97 (IH, 
doublet, C4), 7.75 (2H, multiplet, C6,7), 7.66 (1H, triplet, C3), 
7.41 (1H, doublet, C2), 3.71 (2H, triplet, CH2), 3.35 (4H, 
triplet, 2 x CH2), 2.87 (4H, triplet, 2 × CH2), 2.71 (2H, triplet, 
CH2), 1.61 (1H, singlet, OH) ppm; MS: 337 (M + 1, 100070), 338 
(M+2, 21070), 339 (M+3, 7070). 
2.2. Synthesis ofanthraquinone-piperazinyl phosphoramidite 
1-[1-(2-Hydroxyethyl)piperazinyl]anthraquinone (336 mg, 1 
mmol) was dissolved in CH2C12 (2 ml), and N-ethyldiisopropyl- 
amine (760/zl, 4 mmol) and N,N-diisopropylmethylphosphon- 
amidic chloride (194/zl, 1 mmol) were added. After 30 min the 
solution was poured into ethyl acetate (5 ml, previously washed 
with 2 x 5 ml of 5070 NaHCO3, and 2 x 5 ml saturated NaCI). 
The ethyl acetate phase was dried over Na2SO4 and evaporated 
to an oil. TLC on silica gel (ethyl acetate/triethylamine, 9: 1)
showed complete reaction (Rf of starting material 0.3, Rf of 
product 0.7). 3~p NMR spectroscopy of the product at 
162 MHz gave a single peak at 148.048 ppm of the product N- 
anthraquinonyl-O-methoxydiisopropylamino phosphite 1-(2- 
hydroxyethyl)piperazine (fig.2). 
2.3. Preparation of anthraquinone methylene-linked 
phosphoramidite 
Preparation of the methylene-linked anthraquinone 
phosphoramidite was accomplished as described above, but 
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Fig.2. Synthesis of an anthraquinone 5'-piperazinyl-linked oligodeoxynucleotide viaan intermediate linked phosphoramidite. 
with substitution of the hexamethylene linker, AQ-(CH2)~-OH. 
mH and 3Xp NMR spectra and MS were consistent with the 
purified product (fig. 1). 
2.4. Synthesis of anthraquinone-linked ODNs 
Without further purification the anthraquinone-linked 
phosphoramidites were dissolved in the appropriate amount of 
acetonitrile and used directly in oligonucleotide preparation. 
Oligonucleotides, including phosphorothioate analogs, were 
synthesized as in [30] on an Applied Biosystems 380B syn- 
thesizer with the anthraquinone group attached at the 5'-end; 
a 15-mer all-PO (60% yield), the same all P-S (40% yield), a 
28-mer all-PO (40% yield), the same alI-PS (30% yield). The 
anthraquinone-containing oligomers were characterized byUV, 
and ~H and 3~p NMR. A 1H NMR spectrum of the aromatic 
region of anthraquinonylpiperazinyl-5 '-dT4 is shown in fig.3, 
in which the protons of both the thymine and anthraquinone 
moieties are assigned by comparison with precursors. 
2.5. Melting temperatures 
Melting curves were determined as described [30], using a 
Gilford Response II automatic temperature-adjusting spec- 
trophotometer. In fig.4 we present the melting curves of normal 
and phosphorothioate piperazinyl-linked anthraquinone 
oligothymidines. The reduction in T= due to sulfur substitution 
is similar to the reported value for these compounds [30]. The 
Tm values of both piperazinyl- and methylene-linked anthra- 
quinones, compared to the appropriate oligo controls, are in- 
creased by approx. 6-12°C (table 1). These results indicate that 
the anthraquinone moiety is intercalated in each case, and that 
the difference between heterocyclic and methylene linkers is 
minimal. We also report the Tm of the oe-rev HIV sequence, 
which shows that, as expected for a 28-mer, the increase in Tm 
due to intercalation is small, but not negligible in the case of the 
persulfurized oligo. It is noteworthy that the A Tm is approx. 
2-fold greater for the phosphorothioated anthraquinone com- 
pounds vs the normal inked oligodeoxynucleotides. 
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Fig.3. ~H NMR spectrum at 400 MHz of the aromatic region of the anthraquinone 5'-piperazinyl phosphorothioate tetrathymidylate 
(AQ-p-S-dT4). The individual anthraquinone and thymidine resonances are of equal area. 
3. RESULTS AND DISCUSSION 
Our main objective is to obtain oligodeoxy- 
nucleotides and analogs with covalently attached 
groups that confer biological activity upon the 
product. To accomplish this we synthesized oligo- 
deoxynucleotides in the automatic synthesizer with 
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Fig.4. Melting curves of normal and phosphorothioate 
oligodeoxynucleotides with and without attached 5'-piperazi- 
nylanthraquinones (AQ-p-dTt2) with poly(i'A). The Tm values 
are listed in table 1. Conditions and curve fitting were as 
described in [30]. 
5' covalently attached chemical groups via inter- 
mediate linked phosphoramidites. 
This approach was chosen as an efficient 
method of  obtaining reasonable yields of  the 
desired linked product. Other more standard pro- 
cedures, including synthesis of  the oligo followed 
by covalent attachment of  the linker and/or the 
desired chemical group outside the automatic syn- 
thesizer, or linkage to positions other than the 
5 '-terminus (such as 3'- and/or at intermediate 
Table 1 
Melting temperatures of oligodeoxynucleotides with poly(rA) 
Oligo Tm A Tm AH 
O-dTl2 33.1 33.6 
S-dT12 7.5 - 25.6 32.5 
AQ-m-O-dTlz 41.3 8.2 60.6 
AQ-m-S-dT12 19.2 11.7 31.9 
AQ-p-O-dT12 39.5 6.4 65.0 
AQ-p-S-dT12 18.0 10.5 43.0 
AQ-p-O-dTs 27.5 50.8 
AQ-p-S-dTs - - 
O-a-rev 78.6 
S-a-rev 66.8 - 11.8 
AQ-O-a-rev 81.4 2.8 
AQ-S-~-rev 71.5 4.7 
Tm and ATm are expressed in °C, AH in kcal/mol 
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points within the oligo) could also be used to at- 
tach such groups. 
A novel example described here is the synthesis 
of anthroquinone 5'-l inked to a series of 
oligodeoxynucleotides of different base sequences 
by two kinds of linkers, methylene and 
piperazinyl. This is an example of a wide range of 
feasible compounds of general form R-L-ODN, 
where R represents the attached group, L is a 
linker arm, and ODN is the oligodeoxynucleotide. 
The ODN in this case can be either a normal oligo 
or a chemically modified analog, such as a 
phosphorothioate (containing PS), or a copolymer 
combination of both. An important and novel 
aspect of our work is that such covalently linked 
groups have not previously been attached to 
phosphate-modified (such as PS-containing 
oligos), but only to normal phosphate oligos. 
In the present work, an anthroquinone 
derivative was linked via either a hydroxyethyl- 
piperazinyl (fig.2) or a methylene bridge (fig.l) to 
an ODN. Piperazinyl was chosen as a tertiary 
amine that was expected to stabilize the link. A 
diisopropyl phosphoramidite (diisopropylamino 
phosphite) O-methyl ester was prepared from 
these compounds. This was then attached via the 
standard nucleotide cycle to the 5'-end of an oli- 
gonucleotide chain in the automatic synthesizer. 
The products were characterized by the usual 
methods (1H NMR, 31p NMR, UV, MS), and 
purified by HPLC.  Measurements of Tm values in- 
dicate that intercalation of the anthraquinone oc- 
curs with both linkers (table 1). Specific base 
sequences that were synthesized with 5'- l inked an- 
throquinone are: dT1, dT4, dT8, dT12, dTl~, dC15, 
and anti-sense phosphorothioate oligos" c-myc 
15-mer [8,9] and the anti-rev (S-cr-rev) HIV se- 
quence: d(5 ' -AQ-TCG TCG CTG TCT CCG CTT 
CTT CCT GCC A) [7]. 
The anthraquinone-ODNs described here ex- 
hibited anti-HIV activity in an in vitro assay 
system [31], and can be expected to show other an- 
tiviral properties. The anthroquinone group is an 
oxidizing agent and radical-producing moiety, and 
the oligonucleotide is regarded as a means of 
delivering the group (R) to a biological site 
(mRNA, for example) where it can cause destruc- 
tion and/or  bind (intercalate) to prevent normal 
biological functioning. Other groups that could be 
attached in a similar manner to that described here 
include other anthraquinones [32], and known 
drugs, such as adriamycin and bleomycin. 
These compounds would then be used as drugs 
to inhibit or to attenuate viral activity or mam- 
malian gene (oncogene) expression. The choice of 
base sequence of the ODN and/or the type of 
ODN analog would depend on the target sequence 
in the target gene chosen. The results of inhibition 
by the S-oe-rev sequence in an in vitro T-cell viral 
gag protein assay have been compared with the 
same sequence 5'- l inked to acridine [13] and an- 
thraquinone. The latter was the most effective 
(10-fold vs unlinked sequence)at inhibiting HIV 
expression [31]. While the anthraquinone increases 
the stability of the S-a~-rev hybridization (table 1), 
the difference is not thought o be sufficient o give 
rise to such a biological effect. Further studies 
regarding the mechanism of this effect and the syn- 
thesis and testing of these and other linked com- 
pounds are in progress. 
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